C 19 H 19 NO7, monoclinic, P21/n (no. 14), a = 9.140(2) Å,
Source of material
A mixture of 4-hydroxy-6-methyl-pyran-2-one (10 mmol), 4-hydroxy-3-methoxybenzaldehyde (10 mmol), ethyl cyanoacetate (10 mmol) and 4-(dimethylamino)pyridine (DMAP) (1 mmol) in ethanol (100 mL) was refluxed for 2-3 h and then cooled to room temperature. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried under a vacuum.
Experimental details
H atoms bonded to C and N atoms were positioned geometrically and refined using a riding model, with C-H = 0.93/0.96 Å and N-H = 0.86 Å with U iso (H) = 1.2 times Ueq(C) and 1.2 times Ueq(N).
Comment
Many molecules containing a pyran moiety exhibit interesting pharmacological properties and biological activities [4, 5] .
As an ongoing part of our investigations, we report the preparation and structure of the title compound.
In the crystal structure of the title compound ( Figure) , one methyl group is connected to the ring with the keto function. One ethyl ester group and one amino group are linked to the pyran ring, one phenyl group is connected to the pyran ring by C12-C13 atoms. All bond lengths fall in their normal ranges compared with those in previously studies. The features of the title compound are similar with those in the compound 2-amino-7-methyl-5-oxo-4-phenyl-4H,5Hpyrano [4,3-b] pyran-3-carbonitrile [6] . But there are many more crystal structures which feature the 4H,5H-pyrano- [4,3-b] pyran core (for example see [7, 8] ).
